CQDM congratulates Variational AI (VAI) on announcing a major two-year partnership with Merck, valued at up to USD $349 million. This collaboration aims to accelerate the discovery of new medicines using Enki™, VAI’s cutting-edge generative artificial intelligence platform.
CQDM is proud to have played a pivotal role in launching this journey through its Quantum Leap program, which supported the initial project between VAI and Merck in 2023.
Learn more about this project 👉 Click here.
This achievement reflects CQDM’s mission: to accelerate therapeutic innovation, strengthen the competitiveness of Quebec’s and Canada’s biopharmaceutical sector, and foster high-impact strategic partnerships.
👉 Read the full press release
👉 Learn more about the Quantum Leap program
This program is designed to connect innovative Canadian biotech companies with global pharmaceutical leaders, driving research and innovation in the life sciences.
